- The U.S. administration does not plan to implement tariffs on generic drugs.
- Section 232 tariffs under the Trade Expansion Act are still being considered for branded medicines.
- Officials are exploring loans or grants to boost domestic generic drug manufacturing.
- Concerns about possible price hikes and shortages from tariffs influenced the decision.
- Nearly half of U.S. generics are sourced from India, highlighting reliance on foreign suppliers.
The U.S. administration has decided against imposing tariffs on generic pharmaceuticals, according to statements provided by a White House spokesperson. This follows months of internal discussions regarding the potential use of tariffs under Section 232 of the Trade Expansion Act, which allows such measures on national security grounds.
Earlier, there were proposals for a 100% tariff on name-brand drugs, initially set to begin on October 1, but generic drugs were excluded from this plan. More recently, the move was postponed to allow for further negotiations, as reported by The Wall Street Journal. Commerce Department officials confirmed that there are currently no plans to apply tariffs to generic medications.
White House spokesperson Kush Desai stated, “The administration is not actively discussing imposing Section 232 tariffs against generic pharmaceuticals.” The Commerce Department, leading the investigation, echoed this position. Desai further explained that the administration is taking “a nuanced and multi-faceted approach to onshore manufacturing of generic pharmaceuticals” in order to reduce reliance on overseas production.
Throughout policy discussions, some administration members warned that tariffs on generic medicines, many produced in India, could lead to higher prices and supply disruptions. India supplies almost half of the generic drugs dispensed in the United States. In response to these concerns, officials are also looking at options like federal grants or low-interest loans to encourage U.S.-based production, possibly using funds from tariff arrangements with allied countries such as Japan.
Analysts have cited disruptions during the COVID-19 pandemic as evidence of vulnerabilities in pharmaceutical supply chains. The administration has faced pressure from supporters of reshoring critical industries, though some protectionist lawmakers continue to advocate for broader tariff use. Trade officials said they are reviewing which economic strategies could best support domestic manufacturing, as generic drugs currently face few import restrictions.
Previous Articles:
- Jupiter to Launch JupUSD Stablecoin on Solana With Ethena Labs
- Wall Street Raises S&P 500 Targets Ahead of Q3 Earnings Season
- AMD Hits Record High After Nvidia CEO Calls OpenAI Stake “Imaginative”
- TransCrypts Raises $15M Led by Pantera to Expand Blockchain IDs
- Whale Buys Signal Hope as Hedera HBAR Risks 10% Price Dip
